Is Wei Mingzan included in medical insurance?

On June 2, 20 19, Bio-marin Pharmaceutical Company announced that Weimingzan, a drug for treating rare diseases, was approved for listing by the State Pharmaceutical Products Supervision and Administration for the treatment of mucopolysaccharide storage patients. It is the first mucopolysaccharide storage drug in China, and it is also the first batch of varieties in China's "Catalogue of Overseas New Drugs in Urgent Need of Clinic". Due to the high drug price, the Chinese Medical Association has not included it in the scope of medical insurance, and it needs to wait for the research and development of the corresponding drugs.